Eli Lilly and Company (NYSE:LLY) Shares Sold by Wolf Group Capital Advisors

Wolf Group Capital Advisors lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 57.9% during the first quarter, Holdings Channel.com reports. The fund owned 2,292 shares of the company’s stock after selling 3,148 shares during the period. Wolf Group Capital Advisors’ holdings in Eli Lilly and Company were worth $1,893,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Knightsbridge Asset Management LLC increased its stake in shares of Eli Lilly and Company by 1.9% during the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock valued at $628,000 after acquiring an additional 15 shares during the period. LS Investment Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after acquiring an additional 40 shares during the period. CSM Advisors LLC increased its stake in shares of Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock valued at $807,000 after acquiring an additional 245 shares during the period. Proficio Capital Partners LLC increased its stake in shares of Eli Lilly and Company by 30.2% during the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company’s stock valued at $5,202,000 after acquiring an additional 1,562 shares during the period. Finally, Bfsg LLC increased its stake in shares of Eli Lilly and Company by 1.4% during the first quarter. Bfsg LLC now owns 2,959 shares of the company’s stock valued at $2,444,000 after acquiring an additional 42 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.0%

Eli Lilly and Company stock opened at $791.61 on Wednesday. The company has a 50 day moving average price of $777.90 and a 200 day moving average price of $801.70. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a market capitalization of $750.24 billion, a price-to-earnings ratio of 64.41, a P/E/G ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter in the previous year, the company earned $2.58 EPS. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were given a $1.50 dividend. The ex-dividend date was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. Eli Lilly and Company’s payout ratio is 48.82%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 target price for the company. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, June 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.